Platinum-containing cancer drugs have different mechanisms | Chemical & Engineering News
Volume 95 Issue 10 | p. 11 | Concentrates
Issue Date: March 6, 2017

Platinum-containing cancer drugs have different mechanisms

Unlike cisplatin, oxaliplatin works by inducing ribosome biogenesis stress
Department: Science & Technology
News Channels: Biological SCENE
Keywords: oncology, cisplatin, oxaliplatin, platinum-containing drugs

Platinum-containing drugs are used to treat many types of cancer. Drugs such as carboplatin and oxaliplatin were developed to avoid some of the side effects and treatment resistance associated with traditional cisplatin. Researchers thought all these drugs kill cells by triggering a DNA-damage response. But oxaliplatin has an unusual side-effect profile and works against cancers for which other drugs, such as cisplatin, are minimally effective. A team led by Michael T. Hemann and Stephen J. Lippard of MIT now demonstrates that oxaliplatin works through a different mechanism (Nat. Med. 2017, DOI: 10.1038/nm.4291). The researchers used RNA interference to target genes with known or suspected roles in cell-death signaling pathways and to see how those pathways responded to various platinum-containing drugs. They found that instead of killing cells through DNA damage, oxaliplatin induces ribosome biogenesis stress, in which cells produce large quantities of the protein-translation machinery, throwing protein production out of whack. In a bit of a vicious cycle, ribosome biogenesis stress may further sensitize cells to oxaliplatin. The findings suggest that platinum drugs don’t necessarily function interchangeably with their derivatives, the researchers note.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment